Type 1 Diabetes Management With Technology: Patterns of Utilization and Effects on Glucose Control Using Real-World Evidence

2021 ◽  
pp. cd200098
Author(s):  
Ran Sun ◽  
Imon Banerjee ◽  
Shengtian Sang ◽  
Jennifer Joseph ◽  
Jennifer Schneider ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real World ◽  
Glucose Control ◽  
Diabetes Management ◽  
Real World Evidence ◽  
Patterns Of Utilization

scholarly journals Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes

2019 ◽  
Vol 40 (6) ◽  
pp. 1521-1546 ◽  
Author(s):  
Rayhan A Lal ◽  
Laya Ekhlaspour ◽  
Korey Hood ◽  
Bruce Buckingham
Keyword(s):  
Type 1 Diabetes ◽  
Glucose Control ◽  
Closed Loop ◽  
Diabetes Management ◽  
Artificial Pancreas ◽  
Loop System ◽  
Closed Loop Control ◽  
Closed Loop System ◽  
Loop Control

Abstract Recent, rapid changes in the treatment of type 1 diabetes have allowed for commercialization of an “artificial pancreas” that is better described as a closed-loop controller of insulin delivery. This review presents the current state of closed-loop control systems and expected future developments with a discussion of the human factor issues in allowing automation of glucose control. The goal of these systems is to minimize or prevent both short-term and long-term complications from diabetes and to decrease the daily burden of managing diabetes. The closed-loop systems are generally very effective and safe at night, have allowed for improved sleep, and have decreased the burden of diabetes management overnight. However, there are still significant barriers to achieving excellent daytime glucose control while simultaneously decreasing the burden of daytime diabetes management. These systems use a subcutaneous continuous glucose sensor, an algorithm that accounts for the current glucose and rate of change of the glucose, and the amount of insulin that has already been delivered to safely deliver insulin to control hyperglycemia, while minimizing the risk of hypoglycemia. The future challenge will be to allow for full closed-loop control with minimal burden on the patient during the day, alleviating meal announcements, carbohydrate counting, alerts, and maintenance. The human factors involved with interfacing with a closed-loop system and allowing the system to take control of diabetes management are significant. It is important to find a balance between enthusiasm and realistic expectations and experiences with the closed-loop system.

Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit

2017 ◽  
Vol 35 (1) ◽  
pp. 63-71 ◽  
Author(s):  
A. H. Heald ◽  
M. Livingston ◽  
A. Fryer ◽  
G. Y. C. Moreno ◽  
N. Malipatil ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Real World ◽  
Real World Evidence

scholarly journals Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives

2021 ◽  
Author(s):  
Federico Boscari ◽  
Angelo Avogaro
Keyword(s):  
Quality Of Life ◽  
Type 1 Diabetes ◽  
Glucose Control ◽  
Diabetes Management ◽  
Treatment Options ◽  
Artificial Pancreas ◽  
Glucose Monitoring ◽  
Current Treatment

AbstractType 1 diabetes mellitus imposes a significant burden of complications and mortality, despite important advances in treatment: subjects affected by this disease have also a worse quality of life-related to disease management. To overcome these challenges, different new approaches have been proposed, such as new insulin formulations or innovative devices. The introduction of insulin pumps allows a more physiological insulin administration with a reduction of HbA1c level and hypoglycemic risk. New continuous glucose monitoring systems with better accuracy have allowed, not only better glucose control, but also the improvement of the quality of life. Integration of these devices with control algorithms brought to the creation of the first artificial pancreas, able to independently gain metabolic control without the risk of hypo- and hyperglycemic crisis. This approach has revolutionized the management of diabetes both in terms of quality of life and glucose control. However, complete independence from exogenous insulin will be obtained only by biological approaches that foresee the replacement of functional beta cells obtained from stem cells: this will be a major challenge but the biggest hope for the subjects with type 1 diabetes. In this review, we will outline the current scenario of innovative diabetes management both from a technological and biological point of view, and we will also forecast some cutting-edge approaches to reduce the challenges that hamper the definitive cure of diabetes.

scholarly journals Type 1 Diabetes Management With Technology: Patterns of Utilization and Effects on Glucose Control Using Real-World Evidence

2021 ◽  
Author(s):  
Ran Sun ◽  
Imon Banerjee ◽  
Shengtian Sang ◽  
Jennifer Joseph ◽  
Jennifer Schneider ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Language Processing ◽  
Diabetes Management ◽  
Clinical Care ◽  
Glucose Monitoring ◽  
Diabetes Diagnosis ◽  
Cohort Identification ◽  
Patterns Of Utilization ◽  
Device Use

<b>Key Points</b> <p>· About one-third of patients with type 1 diabetes were found to use continuous glucose monitoring (CGM) and/or continuous subcutaneous insulin infusion (CSII) in routine clinical care.</p> <p>· Disparities exist in CGM and CSII adoption, with device use more common in patients of higher socioeconomic status.</p> <p>· Mining clinical narratives with natural language processing techniques can be applied successfully for medical device surveillance and cohort identification for observational studies.</p> <p>· CGM use in conjunction with CSII after type 1 diabetes diagnosis is more effective than other therapy regimens and may translate to improved long-term glycemic control. </p>

scholarly journals Type 1 Diabetes Management With Technology: Patterns of Utilization and Effects on Glucose Control Using Real-World Evidence

2021 ◽  
Author(s):  
Ran Sun ◽  
Imon Banerjee ◽  
Shengtian Sang ◽  
Jennifer Joseph ◽  
Jennifer Schneider ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Language Processing ◽  
Diabetes Management ◽  
Clinical Care ◽  
Glucose Monitoring ◽  
Diabetes Diagnosis ◽  
Cohort Identification ◽  
Patterns Of Utilization ◽  
Device Use

<b>Key Points</b> <p>· About one-third of patients with type 1 diabetes were found to use continuous glucose monitoring (CGM) and/or continuous subcutaneous insulin infusion (CSII) in routine clinical care.</p> <p>· Disparities exist in CGM and CSII adoption, with device use more common in patients of higher socioeconomic status.</p> <p>· Mining clinical narratives with natural language processing techniques can be applied successfully for medical device surveillance and cohort identification for observational studies.</p> <p>· CGM use in conjunction with CSII after type 1 diabetes diagnosis is more effective than other therapy regimens and may translate to improved long-term glycemic control. </p>

Sign in / Sign up

Export Citation Format

Share Document